Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis
AssigneesNational University Corporation Tottori University, KanonCure, Inc.
InventorsGoshi SHIOTA, Noriko ITABA, Minoru MORIMOTO, Hiroyuki OKA, Kenichiro ABE, Hiroki SHIMIZU, Yoohei KOUNO, Satoshi YOKOGI
Life of this patent
Estimating the term…
Abstract
To obtain a novel therapeutic drug for a malignant tumor or fibrosis. Used is a compound represented by formula (1), a salt thereof, or a solvate thereof. Also used is a therapeutic drug for a malignant tumor or a therapeutic drug for fibrosis, comprising a compound represented by formula (1), a salt thereof, or a solvate thereof.
Claims10
A compound, a salt thereof, or a solvate thereof, the compound represented by formula (1):
- wherein substituents R1 and R2 are represented by the following case (a) or (b):
- (a) R1 is optionally substituted phenyl, and
- R2 is H, optionally substituted phenyl, or —C(O)NHR3 where the R3 is H, C1-6 alkyl, or optionally substituted benzyl;
- or
- (b) R1 is optionally substituted naphthyl or optionally substituted phenyl, and
- R2 is optionally substituted phenyl or —C(O)NHR4 where the R4 is H, C1-6 alkyl, or optionally substituted siloxybenzyl.
8-9. (canceled)
A method of treating a malignant tumor, comprising the step of administering simultaneously or separately to a patient 5-FU and a compound, a salt thereof, or a solvate thereof, the compound represented by formula (2):
- wherein R7 and R8 are the same or different and each represent optionally substituted C1-6 alkyl or optionally substituted C2-6 alkenyl.
A method of treating a malignant tumor, comprising the step of:
- administering to a patient a compound, a salt thereof, or a solvate thereof, wherein the patient has already received 5-FU, the compound represented by formula (2):
- wherein R7 and R8 are the same or different and each represent optionally substituted C1-6 alkyl or optionally substituted C2-6 alkenyl, or
- administering to a patient 5-FU, wherein the patient has already received a compound, a salt thereof, or a solvate thereof, the compound represented by formula (2).
Dependencies are inferred from the claim text.